Treatment of TRAPS with etanercept: use in pediatrics.
Nigrovic
P A
PA
Sundel
R P
RP
D000293:Adolescent; D015703:Antigens, CD / Q000235:genetics; D004247:DNA / Q000032:analysis; D004252:DNA Mutational Analysis; D000068800:Etanercept; D005076:Exanthema; D005220:Fathers; D005260:Female; D005335:Fever of Unknown Origin; D030342:Genetic Diseases, Inborn / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D018095:Germ-Line Mutation; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D017354:Point Mutation; D018124:Receptors, Tumor Necrosis Factor / Q000235:genetics / Q000627:therapeutic use*; D047888:Receptors, Tumor Necrosis Factor, Type I; D013577:Syndrome; D016896:Treatment Outcome
D015703:Antigens, CD; D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D004247:DNA; D000068800:Etanercept